Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8353 + Selumetinib in Advanced Solid Tumors
NCT03745989Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of mk-8353 in solid tumor (advanced stage) and metastatic solid tumor, sponsored by Merck & Co. Primary endpoints: Number of Participants Experiencing Dose Limiting Toxicities, Number of Participants Experiencing Adverse Events and 1 more. Started Feb 2019; status: completed.
02
Drugs
mk-8353
03
Conditions
solid tumor (advanced stage)metastatic solid tumor
Beyond the preview
Go deeper on NCT03745989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03745989.